FDA-approved peptide drugs are just patent-extending pharma plays without meaningful clinical advance

The strongest form of this critique deserves to be conceded before it is contested. Pharmaceutical patent extension is not a paranoid invention; it is a documented commercial practice with its own academic literature, its own regulatory-law sub-discipline, and an active federal enforcement posture. The canonical framing for the broader pattern — old molecule, new patent, new price — is Greene and Riggs's NEJM essay on the absence of generic insulin (Greene JA, Riggs KR, N Engl J Med 2015, 372:1171-1175), which traces almost a century of incremental insulin reformulation as a case study in how a 1920s biologic became a 2010s pricing crisis without a clean generic-entry pathway. The structural review of high US drug prices by Kesselheim, Avorn, and Sarpatwari (JAMA 2016, 316:858-871) maps the toolkit — formulation modifications, pediatric-extension exclusivity, orphan-drug exclusivity, patent thickets, evergreening filings — and the Federal Trade Commission's 2023-2024 challenges to Orange Book listings on inhaler and autoinjector devices reflect the current enforcement frontier. The critique sits on real ground.

The mistake is treating "patent-extending" and "clinically meaningful" as mutually exclusive categories. A drug can be commercially structured to maximize exclusivity and deliver a clinically meaningful outcome over the prior standard of care; the two propositions are independently evaluable, and lumping them is the rhetorical move that does most of the work in the strong form of this objection.

The disambiguation that follows from the literature has three parts. First: is the molecule itself a meaningful pharmacological departure from the prior molecule, or a minor structural variation on it? Second: does the clinical-outcome dataset — randomized-trial endpoints, not in-class extrapolation — show a benefit over the relevant comparator? Third: is the pricing-versus-marginal-benefit ratio defensible? Each can be answered separately for each peptide approval, and the answers are not the same across the corpus.

Where the critique mostly holds. The compounded-versus-branded GLP-1 pricing differential — sometimes 5-15x for clinically equivalent molecules — reflects a commercial and intellectual-property structure far more than a clinical-outcome difference; the /critic/compounded-glp1-equivalence-myth treatment unpacks where the equivalence claim holds and where it does not, and /critic/generic-semaglutide-will-solve-costs-myth addresses what a post-LOE landscape will and will not deliver. Several GnRH-agonist depot reformulations — the leuprolide and histrelin progression from 1-month to 3-month to 6-month to 12-month dosing intervals — are dosing-convenience advances that re-clock intellectual property without obvious pharmacological advance over the prior depot. Some second- and third-line androgen-deprivation combinations in metastatic castration-resistant prostate cancer have produced real progression-free survival gains that are small in absolute terms and priced severely; the critique that the marginal-benefit-per-dollar ratio is poor in this segment is defensible on its own terms even when the underlying randomized-trial outcomes are statistically positive.

Where the critique loses the thread. The SELECT trial of semaglutide in non-diabetic patients with obesity and established cardiovascular disease (Lincoff et al. 2023, N Engl J Med 389:2221-2232) randomized 17,604 patients and reported a 20% relative reduction in major adverse cardiovascular events (hazard ratio 0.80, 95% CI 0.72-0.90) over a mean 40 months. The FDA expanded the Wegovy label to include cardiovascular-risk reduction in this population on the strength of the trial. This is novel pharmacology — a GLP-1 receptor agonist demonstrating outcome benefit on hard cardiovascular endpoints in a non-diabetic population — and the "old drug, new patent, no new outcome" framing fails for this specific case. SURMOUNT-OSA reported tirzepatide produced clinically meaningful reductions in apnea-hypopnea index across two Phase III trials in obese patients with moderate-to-severe obstructive sleep apnea (Malhotra et al., N Engl J Med 2024, 391:1193-1205); the FDA approval for OSA followed in December 2024 as a novel indication, not a label extension on a recycled outcome.

The teriparatide example cuts in the opposite direction from the critique's usual framing. The molecule's black-box warning for osteosarcoma — present at first approval in 2002 and the rate-limiting safety concern for its first eighteen years on market — was removed by the FDA in November 2020 after fifteen years of post-marketing surveillance across roughly 2.47 million treated patients showed no excess incidence over the population baseline of approximately 3.4 per million per year (Krege et al., JBMR Plus 2022, 6:e10665). The maximum-duration limit was also removed. This is the inverse pattern from evergreening: an approved peptide whose safety re-grading reflects long-horizon real-world data, not a manufacturer-driven label extension to defend exclusivity.

The somatostatin-analogue and PRRT cases occupy a third position. The CLARINET trial established a non-acromegaly indication for lanreotide on the basis of a progression-free-survival benefit in metastatic enteropancreatic neuroendocrine tumors — median PFS not reached versus 18.0 months for placebo, hazard ratio 0.47 (Caplin et al., N Engl J Med 2014, 371:224-233) — and the NETTER-1 trial subsequently established lutetium-177 dotatate as an entirely novel therapeutic modality, radiolabeled peptide-receptor radionuclide therapy, with a comparable PFS benefit in advanced midgut NETs versus high-dose octreotide (Strosberg et al., N Engl J Med 2017, 376:125-135). NETTER-2 extended the modality to grade 2-3 disease as first-line therapy (Singh et al., Lancet 2024, 403:2807-2817). Calling PRRT a patent-extension play requires ignoring that the modality did not previously exist.

The publication-of-record framing here is narrow on purpose. The patent-extension critique is real, well-documented, and applicable somewhere in the peptide-approval landscape; it is also inapplicable elsewhere. The way to make the critique productive is to bring it case by case, peptide entry by peptide entry, with the molecule's outcome-trial record on one side and the commercial structure on the other. That accounting is what the entries on this site are organized to support — pages for semaglutide, tirzepatide, and the others lay out the evidence for the specific molecule rather than for the class. The sibling treatments at /critic/no-human-rcts and /critic/off-label-peptide-use-is-freedom-of-medicine-myth work the same disambiguation pattern against adjacent objections. A reader who carries the patent-extension critique to the specific entries will find some places where it bites and other places where it does not, which is the most a serious analysis can deliver.